Background: MAO and ChE enzymes are very critical enzymes which regulate the level of neurotransmitters such as acetylcholine and monoamines. Monoamine neurotransmitters and acetylcholine play a very important role in many physiological events. Increase or decrease in the amount of these neurotransmitters is observed in many central nervous system pathologies. Balancing the amount of these neurotransmitters is important in improving the progression of these diseases. Inhibitors of MAO and ChE enzymes are important in symptomatic therapy and delaying progression of a group of CNS disease manifested with memory loss, cognitive decline and psychiatric disturbances like depression.
Objective: In this article, the relationship between CNS diseases and vital role of the enzymes, MAO and ChE, is discussed on the pathophysiologic basis, focusing on drug research.
Conclusion: MAO and ChE enzymes are still a good target for the development of novel drug active substances with optimized pharmacokinetic and pharmacodynamic properties, which can maximize the benefits of current therapy modalities.